P3‐301: Dextromethorphan/quinidine (AVP‐923) phase 2 study for treatment of agitation in Alzheimer's disease: Comparing the enrolled agitation sample with the international psychogeriatric association definition of agitation in cognitive disorders (NCT01584440). (1st July 2015) - Cummings, Jeffrey L.